Evidence map›Paper›PMID 35614155›Full record

ArticleScientific reports2022

Remuscularization with triiodothyronine and β

Nikolay Bogush, Lin Tan, Emmen Naqvi, John W Calvert, Robert M Graham, W Robert Taylor, Nawazish Naqvi, Ahsan Husain

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Effects of T3 Administration onTransplant international : official journal of the European Society for Organ Transplantation · 2023
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Nikolay Bogush *Division of Cardiology, Department of Medicine, Emory University School of Medicine, 3311 WMRB, 323 WMRB, 101 Woodruff Circle, Atlanta, GA, 30322, USA.
Lin Tan *Division of Cardiology, Department of Medicine, Emory University School of Medicine, 3311 WMRB, 323 WMRB, 101 Woodruff Circle, Atlanta, GA, 30322, USA.
Emmen NaqviDivision of Cardiology, Department of Medicine, Emory University School of Medicine, 3311 WMRB, 323 WMRB, 101 Woodruff Circle, Atlanta, GA, 30322, USA.
John W CalvertDepartment of Surgery, Carlyle Fraser Heart Center, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Robert M GrahamVictor Chang Cardiac Research Institute, Sydney, NSW, 2010, Australia.
W Robert TaylorDivision of Cardiology, Department of Medicine, Emory University School of Medicine, 3311 WMRB, 323 WMRB, 101 Woodruff Circle, Atlanta, GA, 30322, USA.
Nawazish NaqviDivision of Cardiology, Department of Medicine, Emory University School of Medicine, 3311 WMRB, 323 WMRB, 101 Woodruff Circle, Atlanta, GA, 30322, USA. nnaqvi@emory.edu.
Ahsan HusainDivision of Cardiology, Department of Medicine, Emory University School of Medicine, 3311 WMRB, 323 WMRB, 101 Woodruff Circle, Atlanta, GA, 30322, USA. ahusai2@emory.edu.
Emory University · USGeorgia Institute of Technology · USVictor Chang Cardiac Research Institute · AU

Funding

Research Trainng in Academic CardiologyT32HL007745 · NHLBI · EMORY UNIVERSITY · PI TAYLOR, WILLIAM ROBERT · 1994 to 2023
$10.6M
Preclinical Consortium to Facilitate Translation of Cardioprotective TherapiesU24HL094373 · NHLBI · UNIVERSITY OF LOUISVILLE · PI BOLLI, ROBERTO · 2010 to 2014
$9.6M
Functional Cardio-MetabolomicsP20HL113452 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI HAZEN, STANLEY L, TANG, WAI HONG WILSON · 2012 to 2016
$4.8M
The Vascular Chymase-Angiotensin II SystemR01HL079040 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI HUSAIN, AHSAN · 2006 to 2014
$3.0M
Cardioprotective Actions of Hydrogen SulfideR01HL092141 · NHLBI · LSU HEALTH SCIENCES CENTER · PI LEFER, DAVID JOSEPH · 2009 to 2013
$1.9M
Hydrogen sulfide attenuates heart failure through Nrf2-mediated signalingR01HL098481 · NHLBI · EMORY UNIVERSITY · PI CALVERT, JOHN WINTER · 2010 to 2014
$1.9M
Development of the Postnatal HeartR01HL127726 · NHLBI · EMORY UNIVERSITY · PI HUSAIN, AHSAN, NAQVI, NAWAZISH ALI · 2016 to 2019
$1.6M
Nitrite Mediated CardioprotectionR01HL093579 · NHLBI · LSU HEALTH SCIENCES CENTER · PI LEFER, DAVID JOSEPH · 2009 to 2012
$1.5M
American Heart Association-American Stroke Association 17GRNT33670975NHLBI NIH HHS P20 HL113452NHLBI NIH HHS R01 HL079040NHLBI NIH HHS R01 HL092141NHLBI NIH HHS R01 HL093579NHLBI NIH HHS R01 HL098481NHLBI NIH HHS R01 HL127726NHLBI NIH HHS T32 HL007745NHLBI NIH HHS U24 HL094373NIH HHS HL094373NIH HHS HL127726NIH HHS T32HL007745
6 · The paper itself

Abstract

Renewal of the myocardium by preexisting cardiomyocytes is a powerful strategy for restoring the architecture and function of hearts injured by myocardial infarction. To advance this strategy, we show that combining two clinically approved drugs, but neither alone, muscularizes the heart through cardiomyocyte proliferation. Specifically, in adult murine cardiomyocytes, metoprolol, a cardioselective β

Indexed as

Myocardial InfarctionVentricular Dysfunction, LeftAdrenergic beta-1 Receptor AntagonistsAnimalsMetoprololMiceMyocardiumMyocytes, CardiacTriiodothyronineVentricular RemodelingAdrenergic beta-1 Receptor AntagonistsMetoprololTriiodothyronine

Identifiers

PMID35614155
PMCPMC9132945
OpenAlexW4281480943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.